脑转移患者治疗后的30天死亡率:颅外原因占主导
该回顾性分析(2011—2021年)纳入因脑转移接受不同治疗的患者,评估放疗外科或其他初始治疗后30天死亡的危险因素。结果显示61%的死亡与脑转移无关,未发生治疗相关死亡(5级毒性),完全意外死亡未观察到。逻辑回归分析识别出9个与30天死亡相关的因素(各赋3—6分),总分0—30分,最高风险组(>16分)83%在30天内死亡且无人生存超过2个月,但超过一半的30天死亡发生在中间风险组。作者认为颅外肿瘤进展是30天死亡的主要原因,所开发的多因素预测模型性能不完全令人满意,需要外部验证。
要点
- 61%的30天死亡原因与脑转移无关,颅外肿瘤进展是主要原因。
- 未发生治疗相关死亡(5级毒性),也未观察到完全意外死亡。
- 最高风险组(>16分)83%在30天内死亡且无人生存超过2个月,但超过一半的30天死亡发生在中间风险组。
核心结论
- 颅外肿瘤进展是30天死亡的主要原因,从完整肿瘤学背景看,几乎没有死亡可被视为相对意外。
- 作者开发了一个多因素预测模型,但模型性能不完全令人满意,目前不能常规应用,因为需要外部验证来确认这一假设生成性发现。
研究设计与样本
- 回顾性分析(2011—2021年)纳入因脑转移接受不同治疗方法的患者,评估放疗外科或其他初始治疗后30天死亡的危险因素。
主要发现
- 61%的患者死亡原因与脑转移无关。
- 未发生治疗相关死亡(5级毒性)。
- 未观察到完全意外死亡,例如事故、自杀或心源性猝死。
- 逻辑回归分析显示9个因素与30天死亡相关(各赋3—6分),每位患者计算总分,范围从0(无30天内死亡危险因素)到30,结果可分为3或4个风险类别。
- 最高风险组(>16分)中83%的患者在30天内死亡,且无人生存超过2个月;但超过一半的30天死亡发生在中间风险类别。
关键数值与推荐
- 30天死亡预测模型总分0—30分,9个因素各赋3—6分,可分为3或4个风险类别。
- 最高风险组定义为>16分,该组83%在30天内死亡,无人生存超过2个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 模型性能不完全令人满意。
- 模型目前不能常规应用。
- 需要外部验证来确认这一假设生成性发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Established prognostic models, such as the diagnosis-specific graded prognostic assessment, were not designed to specifically address very short survival. Therefore, a brain metastases-specific 30-day mortality model may be relevant. We hypothesized that in-depth evaluation of a carefully defined cohort with short survival, arbitrarily defined as a maximum of 3 months, may provide signals and insights, which facilitate the development of a 30-day mortality model. METHODS: Retrospective analysis (2011-2021) of patients treated for brain metastases with different approaches. Risk factors for 30-day mortality from radiosurgery or other primary treatment were evaluated. RESULTS: The cause of death was unrelated to brain metastases in 61%. Treatment-related death (grade 5 toxicity) did not occur. Completely unexpected death was not observed, e.g. accident, suicide or sudden cardiac death. Logistic regression analysis showed 9 factors associated with 30-day mortality (each assigned 3-6 points) and a point sum was calculated for each patient. The point sum ranged from 0 (no risk factors for death within 30 days present) to 30. The results can be grouped into 3 or 4 risk categories. Eighty-three percent of patients in the highest risk group (> 16 points) died within 30 days, and none survived for more than 2 months. However, many cases of 30-day mortality (more than half) occurred in intermediate risk categories. CONCLUSION: Extracranial tumor progression was the prevailing cause of 30-day mortality and few, if any deaths could be considered relatively unexpected when looking at the complete oncological picture. We were able to develop a multifactorial prediction model. However, the model's performance was not fully satisfactory and it is not routinely applicable at this point in time, because external validation is needed to confirm our hypothesis-generating findings.
引用
- Nieder C, Stanisavljevic L, Aanes SG, et al. 30-day mortality in patients treated for brain metastases: extracranial causes dominate. Radiat Oncol. 2022. PMID: 35551618. doi:10.1186/s13014-022-02062-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。